RxDoctor Payments Data

Steven Givner

Low Vision Rehabilitation · Howard Beach, NYNPI 1104821842

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Alcon at 59.1% of the total. That places this record below the midpoint for low vision rehabilitation clinicians in NY, where the typical reported total is $368.

$95in general payments, 2019–2025

Across 5 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$56
  • Oyster Point Pharma, Inc.$23
  • Dompe US, Inc.$16

What the payments were for

  • Food & beverage$95100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon3$56
Oyster Point Pharma, Inc.1$23
Dompe US, Inc.1$16

How this compares

$95 in reported general payments places this provider in the 30th percentile of 20 low vision rehabilitation providers in New York.

See all low vision rehabilitation providers in New York

Medicare billing

Part B allowed, 2024
$639,363
Medicare patients
1,366
Services billed
11,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine322$201,168
XiidraLifitegrast82$53,814
Cyclosporine143$35,698
Loteprednol Etabonate172$25,437
TyrvayaVarenicline Tartrate42$25,122
LumiganBimatoprost60$23,514
AlrexLoteprednol Etabonate72$23,034
RocklatanNetarsudil Mesylat/Latanoprost67$21,640
EysuvisLoteprednol Etabonate45$21,443
SimbrinzaBrinzolamide/Brimonidine Tart72$14,171
LotemaxLoteprednol Etabonate30$10,597
Alphagan PBrimonidine Tartrate34$9,686
CombiganBrimonidine Tartrate/Timolol24$9,459
ZerviateCetirizine Hcl21$9,177
MieboPerfluorohexyloctane/Pf12$8,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$23$25,12242 claims
AlconSimbrinza, Azopt$56$19,77286 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 20 low vision rehabilitation providers in New York.

Other low vision rehabilitation in Howard Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →